{"id":"W4406437743","doi":"10.1093/braincomms/fcaf022","title":"Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials","year":2024,"lang":"en","type":"review","venue":"Brain Communications","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Medical Research Future Fund; UCB Pharma; National Institutes of Health; Department of Industry, Science, Energy and Resources, Australian Government; National Health and Medical Research Council; Eisai Canada; Biogen; Medical Research Council; Epilepsy Society; Eisai; U.S. Department of Defense; Australian Government; Multiple Sclerosis Australia","keywords":"Progressive supranuclear palsy; Disease; Medicine; Clinical trial; Physical medicine and rehabilitation; Neuroscience; Internal medicine; Psychology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006084511,0.001061535,0.004113612,0.003176002,0.0002533732,0.001705848,0.001313781,0.002016274,0.004068679],"category_scores_gemma":[0.01020456,0.0003930198,0.002488035,0.002109591,0.0004934631,0.001191953,0.000712407,0.002029254,0.0009794828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008533372,"about_ca_system_score_gemma":0.002571438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001109,"about_ca_topic_score_gemma":0.002332313,"domain_scores_codex":[0.9978251,0.0009596671,0.0004788452,0.000163322,0.0005058185,0.00006718575],"domain_scores_gemma":[0.9935902,0.004362571,0.001030053,0.0001176928,0.0007765396,0.0001229471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005146989,0.00009512014,0.0003997721,0.09657559,0.001262401,0.0001030761,0.00006988381,0.0003919867,0.0008972241,0.001787258,0.01186551,0.8860376],"study_design_scores_gemma":[0.001424001,0.001784527,0.007053577,0.1920241,0.009106357,0.001532435,0.0001891261,0.0007793493,0.001908208,0.006808453,0.7772722,0.0001175746],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001764932,0.9984295,0.0002944159,0.0002529257,0.0001493412,0.00009315539,0.00006695304,0.00001155313,0.0005256583],"genre_scores_gemma":[0.003083186,0.9943739,0.001376068,0.0003770089,0.0001240874,0.0002676909,0.0001164972,0.00000379751,0.0002776652],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006084511,"threshold_uncertainty_score":0.0321784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3678472055938017,"score_gpt":0.5514229934338847,"score_spread":0.183575787840083,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}